2 Biotech Stocks with Upcoming Big Mover Readouts Worth a Closer Look

An interesting company to diligence is ACRS (Aclaris) - they have 2 Big Mover readouts coming this month for 2 different assets, and their market cap is less than $200M, yet 7 hedge funds hold them. It's very rare for this many hedge funds to hold a company with that market cap. However, in 2021 their market cap was 10X current, and we find that biopharma-focused hedge funds are not in a rush to pull out of holdings where they have lost big. We have not traced the hedge fund holdings back to 2021 so we don't know if that's the case here. We will be selling most if not all our ACRS in our Run-Up portfolio ahead of those upcoming readouts according to Run-Up fund rules.

A similar high risk play with 6 hedge funds holding and less than $100M market cap is ACET. Big Mover readout coming end of year in Lupus. Super high risk / high reward play. We will keep in Run-Up portfolio at least until early Q4.

#ACRS #ACET

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 6/11/25 EJV & AV